Published in Blood Weekly, February 17th, 1997
The U.S. patent application describes a method to produce large numbers of substantially pure populations of two types of immune cells known as CD4 and CD8 T cells from a small sample of blood. The sequential expansion of both CD4 and CD8 T cells in the same culture offers the unique potential to modulate or control the immune response under laboratory conditions. No expensive cell selection step is required.
Alun Davies, Hemosol, said the technology has...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.